Unlocking a New Era of Therapeutic Possibilities for Patients and Physicians

Saphenous Neuromodulation (SAFN)

A New, Disruptive Approach to Treating OAB

Discovered and patented¹ at the University of Toronto by EBT’s co-founder Professor Paul Yoo, saphenous neuromodulation presents totally new possibilities for treating overactive bladder.

SAFN works via a centralized mechanism, making it ideal for intermittent stimulation rather than continuous. This novel target offers numerous advantages over existing neuromodulation targets, including the tibial nerve.

Key Saphenous Nerve Characteristics

  • Allows for targeted nerve stimulation

  • Easy to reach for patient

  • 83%² lower bladder inhibition threshold vs. other targets³ allowing for less energy to deliver therapy


  • More comfortable treatment experience and not limited by motor nerve side-effects

SAFN has been studied in multiple feasibility studies in the US and Canada for OAB and other indications, with results³ equally effective or better than published results for existing therapies and medications.

OAB sufferers, who number roughly 550M worldwide, have the opportunity to experience treatment without the significant side-effects that come with drugs, or the invasiveness and side-effects that come with botulinum toxin or traditional approaches to neuromodulation.

Press Play to Learn About the Mechanism of Action for SAFN for OAB

78%

Response Rate

Data from three feasibility studies³ points to OAB symptom responder rates that are better than third-line therapies, and only mild transient side-effects

¹9,610,442. 9,884,187
²Moazzam, Z. & Yoo, P. (2018). Frequency-dependent inhibition of bladder function by saphenous nerve stimulation in anesthetized rats. Neurourology and urodynamics, 37(2), 592–599.
³Feasibility clinical outcomes, data on file.